Health
Pfizer, BioNTech propose expanding Covid-19 vaccine trial to 44,000 volunteers – Hindustan Times
The initial target figure for the trial was up to 30,000 participants, which the companies said they expect to reach by next week.
Pfizer Inc and BioNTech SE on Saturday proposed to the US Food and Drug Administration (FDA) to expand their Phase 3 pivotal Covid-19 vaccine trial to about 44,000 participants while increasing the diversity of the trial population.
The initial target figure for the trial was up to 30,000 participants, which the companies said they expect to reach by next week.
The proposed expansion would also allow the companies to enroll people as young as 16 and people with chronic, stable HIV, hepatitis C…
-
Noosa News18 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Noosa News20 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News23 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General19 hours agoInternal Revenue Service starts cutting 20,000 workers